Gilead to Acquire CAR T Partner Arcellx for $7.8B

The centerpiece of the takeover is anito-cel, a CAR T therapy under development for relapsed or refractory multiple myeloma. An FDA decision on the therapy is expected by December 2026.
Just days after CEO Daniel O’Day told investors M&A was not an urgent priority for the pharma, Gilead is dropping $7.8 billion to swallow its CAR T partner Arcellx ahead of a potential approval later this year.

Gilead’s offer values Arcellx at $115 per share, a 68% premium on the biotech’s volume-weighted average share price over the last 30 days, according to Gilead’s Monday announcement.

Read more at BioSpace